Glucient Sr (Metformin Hydrochloride)

Glucient Sr is indicated for the management of type 2 diabetes mellitus as part of a comprehensive treatment plan that includes diet and exercise.

• Improves glycemic control in adults with type 2 diabetes.
• Used as monotherapy when diet and exercise alone are insufficient.
• Can be combined with other antidiabetic agents for enhanced effect.
• May be prescribed when other oral hypoglycemics are not tolerated.
• Supports long‑term reduction of hyperglycemia-related complications.

Metformin, the active component of Glucient Sr, may cause a range of side effects. Most are mild and transient, but some require medical attention.

Common

• Gastrointestinal upset such as nausea, abdominal discomfort, or diarrhea.
• Metallic taste in the mouth.
• Decreased appetite.
• Mild headache.
• Unexplained weight loss.

Serious

• Lactic acidosis, a rare but life‑threatening condition.
• Severe skin reactions like Stevens‑Johnson syndrome.
• Persistent vomiting leading to dehydration.
• Significant elevation of liver enzymes.
• Hypoglycemia when combined with other glucose‑lowering drugs.

Before starting Glucient Sr, certain health considerations should be reviewed to ensure safe use.

• Assess renal function; avoid use in severe renal impairment.
• Monitor liver enzymes periodically.
• Use caution in patients with a history of heart failure or unstable cardiovascular disease.
• Evaluate for alcohol consumption, which may increase risk of lactic acidosis.
• Discontinue before any radiographic studies involving iodinated contrast agents.
• Pregnant or breastfeeding women should consult a healthcare professional before use.

Glucient Sr can interact with several medications, affecting its efficacy or safety profile.

Avoid

• Iodinated contrast media used in imaging studies.
• Cimetidine, which may increase metformin plasma concentrations.
• Certain antiretroviral drugs (e.g., didanosine) that raise the risk of lactic acidosis.

Use with caution

• Diuretics that may affect renal function.
• Beta‑blockers, which can mask hypoglycemia symptoms.
• Other antidiabetic agents, especially sulfonylureas, due to additive glucose‑lowering effects.
• ACE inhibitors or ARBs, requiring monitoring of renal function.